Stokes Family Office’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$747K Sell
26,587
-2,131
-7% -$56.7K 0.08% 154
2025
Q4
$715K Buy
28,718
+1,589
+6% +$40.1K 0.07% 162
2025
Q3
$691K Buy
27,129
+1,420
+6% +$35K 0.07% 155
2025
Q2
$623K Sell
25,709
-45,423
-64% -$1.06M 0.07% 145
2025
Q1
$1.8M Buy
71,132
+1
+0% +$26 0.2% 89
2024
Q4
$1.89M Sell
71,131
-4,779
-6% -$130K 0.2% 89
2024
Q3
$2.2M Buy
75,910
+2,219
+3% +$64.7K 0.24% 76
2024
Q2
$2.06M Buy
73,691
+466
+0.6% +$12.8K 0.24% 78
2024
Q1
$2.03M Sell
73,225
-2,033
-3% -$56.4K 0.25% 81
2023
Q4
$2.17M Sell
75,258
-17,429
-19% -$527K 0.29% 75
2023
Q3
$3.07M Sell
92,687
-6,906
-7% -$244K 0.36% 68
2023
Q2
$3.65M Buy
99,593
+1,337
+1% +$52K 0.42% 54
2023
Q1
$4.01M Sell
98,256
-903
-0.9% -$39K 0.5% 46
2022
Q4
$5.08M Buy
99,159
+1,170
+1% +$56.1K 0.65% 35
2022
Q3
$4.29M Sell
97,989
-466
-0.5% -$22.6K 0.61% 36
2022
Q2
$5.16M Buy
98,455
+1,181
+1% +$60.2K 0.7% 35
2022
Q1
$5.04M Sell
97,274
-1,312
-1% -$68.1K 0.67% 36
2021
Q4
$5.82M Buy
98,586
+2,589
+3% +$128K 0.72% 35
2021
Q3
$4.13M Buy
95,997
+697
+0.7% +$30.9K 0.57% 46
2021
Q2
$3.73M Sell
95,300
-1,052
-1% -$40.9K 0.53% 46
2021
Q1
$3.49M Sell
96,352
-2,319
-2% -$82.3K 0.54% 47
2020
Q4
$3.63M Sell
98,671
-2,992
-3% -$110K 0.72% 38
2020
Q3
$3.54M Buy
101,663
+1,104
+1% +$38.7K 0.8% 35
2020
Q2
$3.12M Sell
100,559
-1,049
-1% -$35.6K 0.79% 35
2020
Q1
$3.15M Buy
101,608
+440
+0.4% +$15K 0.84% 30
2019
Q4
$3.76M Buy
+101,168
New +$3.6M 0.84% 29

Other funds holding PFE

Stokes Family Office's PFE Position: Q1 2026 in Review

Stokes Family Office reduced its Pfizer (PFE) stake by 7.4% in Q1 2026, selling an estimated $56.7K and leaving 26,587 shares worth $747K. The position accounts for 0.08% of the portfolio, ranked #154.

Stokes Family Office first reported a position in PFE in Q4 2019 and has held it in 26 quarters since. The position peaked at $5.82M in Q4 2021. 2,939 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Stokes Family Office held 26,587 shares of Pfizer worth $747K as of Q1 2026.
  • Stokes Family Office sold 2,131 Pfizer shares in Q1 2026, an estimated $56.7K.
  • Pfizer made up 0.08% of Stokes Family Office's portfolio in Q1 2026, its #154 holding.
  • Stokes Family Office first reported a position in Pfizer in Q4 2019 and has held it in 26 quarters since.
  • Stokes Family Office's Pfizer position peaked at $5.82M in Q4 2021.
  • 2,939 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Stokes Family Office's 13F filing for Q1 2026, filed 12 May 2026.